Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering,...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
May 19, 2020
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3...
May 13, 2020
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial R
Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following...
Apr 30, 2020
eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Stu
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent...
Apr 27, 2020
eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Rece
Study Presented in Virtual Session at AACR Annual Meeting Provides Evidence of Potential for Zotatifin to Drug an Important Class of...
Apr 6, 2020
GlaxoSmithKline injects US$250mln into US biotech Vir in coronavirus treatment collaboration
Vir's has two candidates that have proved highly potent in neutralising SARS-CoV-2 in live virus-cellular assays GlaxoSmithKline PLC...
Mar 25, 2020
Vir Biotech IDs Two Antibodies That Could Be Effective in Preventing and Treating COVID-19
San Francisco-based Vir Biotechnology indicated it has identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2,...
Mar 18, 2020
CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series
Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors $40 Million Raised by CERo to Facilitate...
Mar 18, 2020
CERo Therapeutics Announces Research Collaboration with Lyell Immunopharma and Completion of Series
-- Research Collaboration to Develop Next Generation Cell-based Therapies for Solid Tumors -- -- $40 Million Raised by CERo to Facilitate...
bottom of page